Search

Displaying results 5471 - 5480 of 6835 in total
  1. Drug

    Glycocholic acid

    go.drugbank.com/drugs/DB02691
    Investigational

    It acts as a detergent to solubilize fats for absorption and is itself absorbed.

  2. Drug

    STC3141

    go.drugbank.com/drugs/DB16475
    Investigational

    STC3141, was investigated in clinical trial NCT04880694 to evaluate its safety and effect in subjects with severe COVID-19 pneumonia.

  3. Drug

    Sigvotatug Vedotin

    go.drugbank.com/drugs/DB18377
    Investigational

    Sigvotatug vedotin (SGN-B6A) is a humanized immunoglobulin G1 anti-integrin beta-6 monoclonal antibody conjugated to monomethyl auristatin E.

  4. Drug

    Honokiol

    go.drugbank.com/drugs/DB19283
    Investigational

    Honokiol is under investigation in clinical trial NCT00966953 (Development of Clinical Method to Determination Triclosan Retention in Plaque Following Brushing.).

  5. Drug

    Rocacetrapib

    go.drugbank.com/drugs/DB15437
    Investigational

    Rocacetrapib is under investigation in clinical trial NCT02156544 (Study to Investigate the Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of CKD-519).

  6. Drug

    Tipifarnib

    go.drugbank.com/drugs/DB04960
    Investigational

    It belongs to the family of drugs called farnesyltransferase inhibitors. It is also called Zarnestra. In June 2005, the FDA issued a Not Approvable Letter for Zarnestra.

  7. Drug

    TRX1

    go.drugbank.com/drugs/DB05863
    Experimental

    TRX1 is a humanized antibody that binds to the CD4 receptor found on a subset of T cells.

  8. Drug

    Morphine glucuronide

    go.drugbank.com/drugs/DB06409
    Investigational

  9. Drug

    Sonpiretigene isteparvovec

    go.drugbank.com/drugs/DB17844
    Investigational

    Developed by Nanoscope Therapeutics, it is being investigated for vision restoration in advanced retinitis pigmentosa (RP).

  10. Drug

    Azelastine

    go.drugbank.com/drugs/DB00972
    ApprovedInvestigational

    [L8240,L8270] It is a racemic mixture, though there is no noted difference in pharmacologic activity between enantiomers, and was first granted FDA approval in 1996.